Abstract
The aim of allergic rhinitis treatment is to control symptoms, but currently considered first-line therapy provides suboptimal symptom relief for many patients. MP29-02 is a new treatment for allergic rhinitis, developed to fill this unmet need. Moderate/severe seasonal allergic rhinitis patients treated with MP29-02 experienced twice the nasal and ocular symptom relief as those treated with azelastine or fluticasone propionate. The effect was consistent across seasons, symptoms and by severity. MP29-02 delivered substantial and complete response in more patients and many days faster than fluticasone propionate or azelastine. Its efficacy advantage over fluticasone propionate extended beyond 14 days, up to 1 year, in chronic rhinitis patients. MP29-02 was well tolerated, both short and long term, and may change the way allergic rhinitis is managed, for the better.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
